Fudan University

GenomiCare Biotechnology Appoints Dr. Shusen Liu as Chief Medical Officer

Retrieved on: 
Thursday, January 20, 2022 - 2:50pm

HAVERFORD, Pa., Jan. 20, 2022 (GLOBE NEWSWIRE) -- GenomiCare Biotechnology, a leader in precision medicine of Chinese cancer patients and the application of RWD to pharmaceutical research and development, today announced the recent appointment of Shusen Liu, M.D., Ph.D., as Chief Medical Officer.

Key Points: 
  • HAVERFORD, Pa., Jan. 20, 2022 (GLOBE NEWSWIRE) -- GenomiCare Biotechnology, a leader in precision medicine of Chinese cancer patients and the application of RWD to pharmaceutical research and development, today announced the recent appointment of Shusen Liu, M.D., Ph.D., as Chief Medical Officer.
  • "We are pleased to welcome Dr. Shusen Liu to GenomiCare Biotechnology as Chief Medical Officer, said Dr. Qiang Xu, GenomiCares President and CEO.
  • On his appointment Dr. Liu said, As Chief Medical Officer of GenomiCare Biotechnology, I am looking forward to taking advantage of my experience in the RWD research and making contributions to the RWD strategy and commercial expansion.
  • His He has also served as Vice President, Chief Medical Evidence Officer, at Digital China Health (DCH).

Advances in the Diagnosis and Treatment of Pancreatic Cancer

Retrieved on: 
Tuesday, January 18, 2022 - 3:33pm

Pancreatic cancer is characterized by an extremely poor prognosis and limited treatment options.Metabolic reprogramming has emerged a novel hallmark of cancers, including pancreatic cancer.

Key Points: 
  • Pancreatic cancer is characterized by an extremely poor prognosis and limited treatment options.Metabolic reprogramming has emerged a novel hallmark of cancers, including pancreatic cancer.
  • Recent studies indicate that alterations in specific metabolic pathways in pancreatic cancer contribute to tumor growth, therapeutic resistance, and immune escape.
  • Nonetheless, the role of metabolic genes in pancreatic cancer has not been elucidated.
  • Dr. Wu and colleagues used theTCGA and GEO databases to discover differentially expressed metabolic genes (DEMGs) in pancreatic cancer.

Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance

Retrieved on: 
Wednesday, January 12, 2022 - 1:26am

Safety data on the phase I clinical trial was released by Director Chen Guiling of Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, and the results indicated high safety and well toleration.

Key Points: 
  • Safety data on the phase I clinical trial was released by Director Chen Guiling of Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, and the results indicated high safety and well toleration.
  • Compared to the phase I clinical trial results of similar products, it demonstrated excellent safety and immunogenicity.
  • At present, the phase I clinical trials of all 3 China's mRNA vaccines are carried out at the Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, among which the first mRNA vaccine is already under phase III clinical trial overseas.
  • At the meeting, top-notch experts acclaimed the phase I results of the mRNA COVID-19 vaccine (LVRNA009) of AIM Vaccine.

Medtronic Announces Approval of the Evolut™ PRO TAVR System in China

Retrieved on: 
Monday, January 10, 2022 - 1:00pm

DUBLIN, Jan. 10, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the National Medical Products Administration (NMPA) has approved the CoreValve™ Evolut™ PRO TAVR system for the treatment of severe aortic stenosis (AS) for symptomatic patients in China who are at high or extreme risk for open heart surgery. As the first Medtronic self-expanding TAVR system approved in China, the Evolut PRO system approval is based on clinical data from more than 32,000 patients, which showed high survival, low rates of stroke, minimal paravalvular leak (PVL) and excellent hemodynamics (blood flow). Full commercial launch is anticipated in early calendar year 2022.

Key Points: 
  • As the first Medtronic self-expanding TAVR system approved in China, the Evolut PRO system approval is based on clinical data from more than 32,000 patients, which showed high survival, low rates of stroke, minimal paravalvular leak (PVL) and excellent hemodynamics (blood flow).
  • The Evolut PRO TAVR system is the next generation of the clinically proven supra-annular CoreValve Evolut R system that provides industry-leading hemodynamic performance.
  • "The Evolut PRO TAVR system has shown impressive clinical outcomes and I look forward to seeing it benefit more patients throughout China."
  • The approval is based on data from high- and extreme-risk patients across Medtronic-sponsored studies and real-world registries with the CoreValve Evolut TAVR platform.

Enfusion Elevates Iris Xinwei Wang to Chief Strategy Officer and Lotte Tønsberg to Head of EMEA Sales and Executive Director, EMEA

Retrieved on: 
Thursday, January 6, 2022 - 1:24pm

Iris Xinwei Wang will serve as Enfusions Chief Strategy Officer, based in New York.

Key Points: 
  • Iris Xinwei Wang will serve as Enfusions Chief Strategy Officer, based in New York.
  • Additionally, Lotte Tnsberg will serve as the London-based Head of Sales for EMEA.
  • We are thrilled to announce the promotion of Iris and Lotte, both of whom have been instrumental in our global expansion, said Thomas Kim, CEO of Enfusion.
  • As Chief Strategy Officer, Iris will serve as the global driver of Enfusions continued strategic expansion, corporate development and transformation.

Gen Zers discuss China-US Relations in China Daily series Youth Power

Retrieved on: 
Thursday, December 30, 2021 - 1:10pm

For the episode, Youth Powerinterviewed young people on the streets of China and the US and talked about politics, culture, economics, education and other topics.

Key Points: 
  • For the episode, Youth Powerinterviewed young people on the streets of China and the US and talked about politics, culture, economics, education and other topics.
  • Gen Zers from both China and the US were also invited to sit down and give their views on the China-US relationship.
  • "The youth of China and the US should both shoulder the responsibility of building a community of a shared future for humankind."
  • "The future of China and the US, for a large part, rests on the shoulders of Chinese and American youth.

DGAP-News: Lisen Imprinting Diagnostics Announces a Revolutionary Early Diagnostic Method for Lung Cancer

Retrieved on: 
Monday, December 20, 2021 - 11:48am

WUXI, CHINA & PHILADELPHIA, PA / ACCESSWIRE / December 15, 2021 / Lisen Imprinting Diagnostics ("LisenID" or "the company") announces an innovative and ground-breaking epigenetics-based diagnostic solution for early lung cancer detection.

Key Points: 
  • WUXI, CHINA & PHILADELPHIA, PA / ACCESSWIRE / December 15, 2021 / Lisen Imprinting Diagnostics ("LisenID" or "the company") announces an innovative and ground-breaking epigenetics-based diagnostic solution for early lung cancer detection.
  • The present study particularly focused on lung cancer, which has the highest reported mortality among all cancers.
  • This method could greatly improve the diagnostic performance of preoperative cytopathology, promote the early diagnosis and treatment of lung cancer, and increase the survival of lung cancer patients.
  • During preoperative detection, the diagnostic model can accurately distinguish benign lung diseases from lung cancer demonstrating far superior diagnostic sensitivity than cytopathology, particularly for early lung cancer and small lung nodules.

New "Solar" Catalyst to Treat Industrial Waste Water Cheap and Fast from NUST MISIS Scientists

MOSCOW, Dec. 13, 2021 /PRNewswire/ -- A new "solar" catalyst based on molybdenum sulfide for water purification was developed by NUST MISIS scientists together with colleagues from FEFU, Fudan University (China) and Tokai University (Japan).

Key Points: 
  • MOSCOW, Dec. 13, 2021 /PRNewswire/ -- A new "solar" catalyst based on molybdenum sulfide for water purification was developed by NUST MISIS scientists together with colleagues from FEFU, Fudan University (China) and Tokai University (Japan).
  • Therefore, scientists are faced with the task of minimizing the amount of harmful emissions, as well as developing effective methods for purifying water from these emissions.
  • Photocatalytic degradation by sunlight is a technology with minimal anthropogenic impact on the environment, as it uses only natural sunlight and a catalyst.
  • Therefore, with the use of non-toxic photocatalysts scientists can create a "green technology" for processing harmful emissions, similar to natural photosynthesis.

New "Solar" Catalyst to Treat Industrial Waste Water Cheap and Fast from NUST MISIS Scientists

MOSCOW, Dec. 13, 2021 /PRNewswire/ -- A new "solar" catalyst based on molybdenum sulfide for water purification was developed by NUST MISIS scientists together with colleagues from FEFU, Fudan University (China) and Tokai University (Japan).

Key Points: 
  • MOSCOW, Dec. 13, 2021 /PRNewswire/ -- A new "solar" catalyst based on molybdenum sulfide for water purification was developed by NUST MISIS scientists together with colleagues from FEFU, Fudan University (China) and Tokai University (Japan).
  • Therefore, scientists are faced with the task of minimizing the amount of harmful emissions, as well as developing effective methods for purifying water from these emissions.
  • Photocatalytic degradation by sunlight is a technology with minimal anthropogenic impact on the environment, as it uses only natural sunlight and a catalyst.
  • Therefore, with the use of non-toxic photocatalysts scientists can create a "green technology" for processing harmful emissions, similar to natural photosynthesis.

Technical Paper on AnPac Bio Novel CDA Cancer Detection Technology Published by Peer-Reviewed International Medical Journal

Retrieved on: 
Friday, December 10, 2021 - 12:30pm

The title of the published paper is Development and Evaluation of Cancer Differentiation Analysis Technology: A Novel Biophysics-Based Screening Method.

Key Points: 
  • The title of the published paper is Development and Evaluation of Cancer Differentiation Analysis Technology: A Novel Biophysics-Based Screening Method.
  • The paper reported the mechanism of CDA technology, as well as an extensive, multi-year, multi-cancer screening validation work that included a two-stage study design.
  • Dr. Chris Yu, AnPac Bios Chairman and CEO commented: We are very pleased with the publication of our technical paper on CDA cancer detection technology by a peer-reviewed international journal in the field of medicine.
  • AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 150 issued patents as of September 30, 2021.